Precision medicine oncology company IDEAYA Biosciences Inc (Nasdaq:IDYA) on Sunday announced the development candidate nomination of IDE101, a potential first-in-class dual cyclin-dependent kinase (CDK) inhibitor designed to address the loss of CDKN2A-mediated tumour suppressor function in cancer.
CDKN2A-deficiency occurs in approximately 10-15% of all solid tumours, including around 70% of pancreatic ductal adenocarcinoma (PDAC), and is typically co-deleted in methylthioadenosine phosphorylase (MTAP)-deficient cancers given their proximity on chromosome 9p21.
IDEAYA says that IDE101 was discovered through its iterative physics-based ligand design and optimisation platform, and is a highly potent and selective dual CDK inhibitor with first-in-class potential and favourable drug-like properties. IND-enabling studies for IDE101 are ongoing to support an Investigational New Drug (IND) filing to the US Food and Drug Administration (FDA) in the first half of 2027, subject to satisfactory completion of ongoing preclinical and IND-enabling studies.
Aelis Farma announces receipt of second positive safety recommendation for Down syndrome trial
Ambrosia Biosciences reports data on two oral small molecule programs at ObesityWeek 2026
Specialised Therapeutics' YONDELIS sarcoma therapy approved in Thailand
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Breakthrough T1D and Walgreens Foundation join forces to support the type 1 diabetes community
PAI Pharma acquires Nexus Pharmaceuticals
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177